Tandem Diabetes Care is positioned for growth driven by rising diabetes prevalence and connected care adoption, but faces macroeconomic and execution risks. The company is expanding its addressable market with Control-IQ+ for type 1 and type 2 diabetes and transitioning to a pay-as-you-go reimbursement model in the U.S. pharmacy channel, which represented 6% of U.S. sales in first-quarter 2026. Management reaffirmed 2026 guidance for revenues of about $1.065 billion to $1.085 billion, gross margin of about 56% to 57%, and adjusted EBITDA margin of about 5% to 6%. Tandem Diabetes ended the first quarter with $570.3 million in cash, cash equivalents, and short-term investments, and no short-term debt. The Zacks Consensus Estimate for 2026 revenues is $1.08 billion, implying 6% growth, while the loss per share estimate stands at 72 cents. The stock carries a Zacks Rank #3.
Tandem Diabetes Care IncGrowing diabetes prevalence and connected care adoption, plus Control-IQ+ expansion into type 2 diabetes, drive demand for Tandem's products.
Integra LifeSciences Holdings
Illumina Inc
Align Technology Inc